A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL)
A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL)
Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
FIL_RICCO
Codice EudraCT
2023-506206-38-00
Sponsor/Promotore
Fondazione Italiana Linfomi Onlus
Tipologia
Sperimentale
Fase
II
Unità Operativa
Oncologia 1
Principal Investigator